DEA Reschedules Hydrocodone Combination Products

Posted in Latest News on September 9, 2014.

On Friday, August 22nd, the U. S. Drug Enforcement Administration (DEA) published a Final Rule moving hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II. This Final Rule imposes the regulatory controls and sanctions applicable to Schedule II substances on those who handle or propose to handle HCPs. The rule goes into effect 45 days from its publish date.



More Latest News

Monoclonal Antibody Therapy Authorized for COVID-19
August 5, 2021

Important Updates Regarding the Revised Emergency Use Authorization, Direct Order, and Reporting Process for REGEN-COV Monoclonal Antibody Therapy Continue reading


Newly Licensed Florida Practitioners Search Tool
July 29, 2021

Click here to access data on recently licensed Health Care Practitioners and Facilities
  Continue reading




Supporting Documents

Medical Degree Verification
NICA FORM
Postgraduate Training Verification
License Verification

Supporting Documents - Visiting Physician

NICA FORM